3. Histologically confirmed mismatch repair deficient or genetic testing confirmed microsatellite instability high tumor.
4. Signed written informed consent.
You may not be if
1. The patient has a history of other serious conditions rendering them unsuitable for surgery.
2. Subjects with the following conditions: active autoimmune diseases, active infectious diseases, inflammatory bowel diseases; requiring long-term glucocorticoid or immunosuppressive therapy during treatment; history of immunodeficiency; history of organ transplantation or haematopoietic stem cell transplantation; severe interstitial pneumonia or pulmonary fibrosis.
3. Known hypersensitivity to any component or excipient of tislelizumab or other PD-1/PD-L1 agents.
4. Other conditions deemed unsuitable for inclusion by the investigator.
Clareo Health | Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
